Antares Pharma (ATRS) Misses Q1 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q1 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $13.3 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Constellation Brands (STZ) Tops Q1 EPS by 18c
• Flowserve acquires Trillium valves division for $490 million
• Alcoa agrees to buy South32 assets for $4.1 billion